Innate Pharma (IPHA) Price & Analysis

Compare

121 Followers

IPHA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.29 - $3.51

Previous CloseN/A

Volume6.24K

Average Volume (3M)11.73K

Market Cap

$197.66M

Enterprise Value$97.93M

Total Cash (Recent Filing)$80.77M

Total Debt (Recent Filing)$31.00M

Price to Earnings (P/E)―

Beta0.26

Next Earnings

Sep 17, 2025

EPS Estimate

-0.33

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.35

Shares Outstanding92,183,525

10 Day Avg. Volume20,106

30 Day Avg. Volume11,726

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.50

Enterprise Value/Revenue7.76

Enterprise Value/Gross Profit7.76

Enterprise Value/Ebitda-2.09

Forecast

1Y Price Target

$8.00

Price Target Upside279.15% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical TrialsPhase 3 Data from the PACIFIC-9 Trial of Monalizumab in Stage 3 NSCLC could be a meaningful catalyst for shares.

Financial StabilityInnate Pharma has sufficient cash and cash equivalents to support operations into mid-2026, providing financial stability.

Product PotentialIPH4502 is a Novel Nectin-4 ADC with potential in post Padcev patients and other solid tumors, addressing a large unmet need and market opportunity.

Bears Say

Investment OutlookSanofi's potential equity investment in IPHA of €15 M is tepid and adds to questions on the outlook for IPH6101.

Product DevelopmentIPH6101 now faces an uncertain future as Innate management did not confirm whether they plan on continuing the Sanofi-initiated Ph 2 study with the ANKET in combination with venetoclax in front-line AML.

Product Launch DelayThe U.S. launch of IPH6101 is postponed to 2029 from previously estimated 2027 and EU launch to 2030 from 2028.

Innate Pharma News

Innate Pharma initiated with a Buy at BTIG

BTIG analyst Justin Zelin initiated coverage of Innate Pharma (IPHA) with a Buy rating and $8 price target...

10d ago

IPHA

Innate Pharma’s IPH4502 Study: A New Hope in Cancer Treatment

INNATE PHARMA (($GB:0EVI)), Innate Pharma SA Sponsored ADR (($IPHA)) announced an update on their ongoing clinical study. Innate...

14d ago

IPHA

Innate Pharma presents preclinical data for IPH6501 at EHA

Innate Pharma (IPHA) announced the presentation of preclinical data for IPH6501, its proprietary Anket targeting CD20 currently under...

2M ago

IPHA

Innate Pharma presents long-term follow-up data from TELLOMAK trial

Innate Pharma (IPHA) announced the presentation of long-term follow-up data from the Phase 2 TELLOMAK clinical trial evaluating...

3M ago

IPHA

Innate Pharma: Navigating Challenges with Promising Pipeline and Strategic Partnerships

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on IPHA stock, giving a Buy rating yesterday....

3M ago

IPHA

Innate Pharma price target lowered to $11 from $11.50 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Innate Pharma (IPHA) to $11 from $11.50 and keeps a...

4M ago

IPHA

Innate Pharma announces EUR 15M capital increase from Sanofi

Innate Pharma (IPHA) announced a EUR 15M capital increase subscribed by Sanofi (SNY). As announced on April 23...

4M ago

SNY

IPHA

Innate Pharma regains rights to Anket, announces potential Sanofi investment

Innate Pharma (IPHA) announced review of its January 2016 research collaboration and license agreement with Sanofi (SNY): As...

4M ago

SNY

IPHA

Innate Pharma: Promising Pipeline and Strategic Developments Drive Buy Rating

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Innate Pharma (IPHA...

4M ago

IPHA

Innate Pharma Reports 2024 Financial Results and Clinical Progress

Innate Pharma SA Sponsored ADR ( ($IPHA) ) has released its Q4 earnings. Here is a breakdown of...

4M ago

IPHA

Buy Rating for Innate Pharma: Lacutamab’s Breakthrough Designation and Market Potential Drive Positive Outlook

In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on Innate Pharma...

6M ago

IPHA

Innovative Potential of Innate Pharma’s IPH4502 in Overcoming Drug Resistance and Expanding Therapeutic Impact

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Innate Pharma (IPHA – Research Report)....

6M ago

IPHA

Innate Pharma doses first patient in IPH4502 study

Innate Pharma (IPHA) announced the first patient was dosed in its Phase 1 study, investigating the safety and...

6M ago

IPHA

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

8M ago

VIR

BCYC

IPHA FAQ

What was Innate Pharma SA Sponsored ADR’s price range in the past 12 months?

Innate Pharma SA Sponsored ADR lowest stock price was $1.29 and its highest was $3.51 in the past 12 months.

What is Innate Pharma SA Sponsored ADR’s market cap?

Innate Pharma SA Sponsored ADR’s market cap is $197.66M.

When is Innate Pharma SA Sponsored ADR’s upcoming earnings report date?

Innate Pharma SA Sponsored ADR’s upcoming earnings report date is Sep 17, 2025 which is in 41 days.

How were Innate Pharma SA Sponsored ADR’s earnings last quarter?

Innate Pharma SA Sponsored ADR released its earnings results on Mar 27, 2025. The company reported -$0.346 earnings per share for the quarter, missing the consensus estimate of -$0.267 by -$0.079.

Is Innate Pharma SA Sponsored ADR overvalued?

According to Wall Street analysts Innate Pharma SA Sponsored ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Innate Pharma SA Sponsored ADR pay dividends?

Innate Pharma SA Sponsored ADR does not currently pay dividends.

What is Innate Pharma SA Sponsored ADR’s EPS estimate?

Innate Pharma SA Sponsored ADR’s EPS estimate is -0.33.

How many shares outstanding does Innate Pharma SA Sponsored ADR have?

Innate Pharma SA Sponsored ADR has 92,183,525 shares outstanding.

What happened to Innate Pharma SA Sponsored ADR’s price movement after its last earnings report?

Innate Pharma SA Sponsored ADR reported an EPS of -$0.346 in its last earnings report, missing expectations of -$0.267. Following the earnings report the stock price went up 8.84%.

Which hedge fund is a major shareholder of Innate Pharma SA Sponsored ADR?

Currently, no hedge funds are holding shares in IPHA

Innate Pharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

-160.99%

Trailing 12-Months

Asset Growth

-43.48%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Innate Pharma SA Sponsored ADR

Innate Pharma S.A. is a clinical-stage biotechnology company based in France, specializing in the discovery and development of therapeutic antibodies that harness the innate immune system to improve cancer treatment. The company's portfolio primarily focuses on immuno-oncology, targeting a variety of cancers through innovative therapies designed to enhance the body's natural immune response.

Innate Pharma (IPHA) Earnings & Revenues

Historic Earnings Reports

IPHA Company Deck

IPHA Earnings Call

Q4 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflected a positive outlook with significant achievements in clinical trial progress, regulatory milestones, and financial stability. However, strategic shifts and decreased R&D expenses indicate some challenges in specific areas.View all IPHA earnings summaries

IPHA Stock 12 Month Forecast

Average Price Target

$8.00

▲(279.15% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","2.25":"$2.25","4.5":"$4.5","6.75":"$6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.84,2.313846153846154,2.787692307692308,3.2615384615384615,3.7353846153846155,4.2092307692307696,4.683076923076923,5.156923076923077,5.630769230769231,6.104615384615385,6.578461538461538,7.052307692307692,7.526153846153846,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.84,2.313846153846154,2.787692307692308,3.2615384615384615,3.7353846153846155,4.2092307692307696,4.683076923076923,5.156923076923077,5.630769230769231,6.104615384615385,6.578461538461538,7.052307692307692,7.526153846153846,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.84,2.313846153846154,2.787692307692308,3.2615384615384615,3.7353846153846155,4.2092307692307696,4.683076923076923,5.156923076923077,5.630769230769231,6.104615384615385,6.578461538461538,7.052307692307692,7.526153846153846,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.54,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.74,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.15,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.46,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.83,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >